Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Clinical Outcomes ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Inotuzumab Ozogamicin ◽

Phase 3 ◽

PCN39 TREATMENT PATTERNS, MINIMAL RESIDUAL DISEASE (MRD) TESTING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PATIENT CHART REVIEW IN BELGIUM, GREECE AND SWITZERLAND

Value in Health ◽

10.1016/j.jval.2019.09.236 ◽

2019 ◽

Vol 22 ◽

pp. S442-S443

Author(s):

A. Spyridonidis ◽

D. Deeren ◽

W. Bouwmeester ◽

C. Giannopoulou ◽

K. Nickel ◽

...

Keyword(s):

Clinical Outcomes ◽

Chart Review ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Treatment Patterns ◽

Patient Chart ◽

Testing Patterns ◽

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

Leukemia Research ◽

10.1016/j.leukres.2019.106283 ◽

2020 ◽

Vol 88 ◽

pp. 106283 ◽

Cited By ~ 9

Author(s):

Elias Jabbour ◽

Nicola Gökbuget ◽

Anjali Advani ◽

Matthias Stelljes ◽

Wendy Stock ◽

...

Keyword(s):

Residual Disease ◽

Lymphoblastic Leukemia ◽

Disease Status ◽

Phase Iii ◽

Inotuzumab Ozogamicin ◽

Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland

Leukemia Research ◽

10.1016/j.leukres.2020.106334 ◽

2020 ◽

Vol 91 ◽

pp. 106334

Author(s):

Dries Deeren ◽

Stefan Balabanov ◽

Katharina Nickel ◽

Christina Giannopoulou ◽

Sebastian Gonzalez-McQuire ◽

...

Keyword(s):

Clinical Practice ◽

Clinical Outcomes ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Treatment Patterns ◽

Routine Clinical Practice ◽

Minimal Residual ◽

Disease Testing

Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes

Transplantation and Cellular Therapy ◽

10.1016/s2666-6367(21)00160-3 ◽

2021 ◽

Vol 27 (3) ◽

pp. S125

Author(s):

Lissette Cervantes ◽

Lan Y Wang ◽

George Yaghmour ◽

Andrei Varnavski ◽

Imran Siddiqi

Keyword(s):

Next Generation Sequencing ◽

Clinical Outcomes ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Disease Detection ◽

Next Generation ◽

Generation Sequencing ◽

Improving Diagnostic Methods for Minimal Residual Disease Detection (MRD) in Childhood Acute Lymphoblastic Leukemia (ALL)

Klinische Pädiatrie ◽

10.1055/s-0034-1374837 ◽

2014 ◽

Vol 226 (03) ◽

Author(s):

A Szymansky ◽

S Groeneveld-Krentz ◽

J Hof ◽

R Kirschner-Schwabe ◽

C Eckert

Keyword(s):

Residual Disease ◽

Lymphoblastic Leukemia ◽

Diagnostic Methods ◽

Childhood Acute Lymphoblastic Leukemia ◽

Disease Detection ◽

Minimal Residual Disease Detection ◽

Faculty Opinions recommendation of Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14267017.15779136 ◽

2012 ◽

Author(s):

Jan Starý ◽

Jana Volejnikova

Keyword(s):

Treatment Outcome ◽

Induction Therapy ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Early Response ◽

Childhood Acute Lymphoblastic Leukemia ◽

Response To Treatment ◽

Faculty Opinions recommendation of Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3974956.3733054 ◽

2010 ◽

Author(s):

Sheila Weitzman ◽

Sumit Gupta

Keyword(s):

Clinical Significance ◽

Induction Therapy ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Childhood Acute Lymphoblastic Leukemia ◽

Remission Induction ◽

Low Levels ◽

Faculty Opinions recommendation of Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718266974.793496733 ◽

2014 ◽

Author(s):

Jan Starý ◽

Michaela Kotrová

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Minimal Residual ◽

Philadelphia Chromosome Positive

Faculty Opinions recommendation of Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725382591.793524768 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

High Risk ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Prognostic Relevance ◽

Ikaros (IKZF1 ) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR /ABL -negative acute lymphoblastic leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.24299 ◽

2012 ◽

Vol 60 (3) ◽

pp. 420-427 ◽

Cited By ~ 10

Author(s):

Jana Volejnikova ◽

Ester Mejstrikova ◽

Petra Dörge ◽

Barbara Meissner ◽

Olga Zimmermannova ◽

...

Keyword(s):

Flow Cytometry ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽